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Abstract  
One-third of the American adult population is considered overweight, a figure that is still on the 
rise. Obesity negatively impacts every organ system in the human body. When minimally 
invasive strategies such as life style changes fail, bariatric surgery procedures have become the 
other option. The purpose of this systemic analysis is to look at the outcomes of post-operative 
pain, post-operative nausea and vomiting (PONV), and the length of stay required in the post-
anesthesia care unit (PACU) in obese adults undergoing bariatric surgery using opioid-free 
general anesthesia compared to opioid-based general anesthesia. The studies included in this 
systematic analysis conclude that adequate post-operative pain management can be achieved 
with an opioid-free anesthetic plan or a decrease in opioid use, which in turn allows for 
extubation to occur in the operating room and less PONV. The length of stay in the PACU has 
been shown to be inconsistent. Some studies indicate no significant difference, whereas others 
show a slight decrease in length of stay in the PACU. However, a correlation between less post-
operative complications, such as PONV incidences, and a decreased length of stay in the PACU 
can be seen. The studies are small and the research on the best anesthetic plan for obese patients 
undergoing bariatric surgery has yet to be established, but what is known is that the use of 
opioids adversely effects obese patients, and more so than non-obese patients. Many obese 
patients suffer from obstructive sleep apnea, decreased functional residual capacity and 
decreased lung compliance. This knowledge coupled with the understanding that this population 
is more sensitive to the respiratory depressant effects of opioids indicates that an opioid-free 
anesthetic may provide better post-operative outcomes.   
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A Literature Review on Opioid-Free General Anesthesia versus Opioid-Based General 
Anesthesia for Bariatric Surgery 
Introduction 
Obesity in the United States is an ever-growing epidemic that not only affects every system 
in the human body, but also has adverse economical and psychological impacts. As a result, 
obesity does not merely affect the individual alone, but an entire society. With a prevalence of 
one-third of adults considered to be overweight (not including childhood obesity, which is 
becoming an epidemic in its own right), more patients are turning to surgery as a solution. In 
1992 there were 16,200 bariatric surgical procedures in the United States and by 2008 that 
number had increased to 220,000 (Schumann, 2010). This paper aims at answering the following 
question: “In obese adults undergoing bariatric surgery, how does opioid-free general anesthesia 
compare to opioid-based general anesthesia and its effect on post-operative outcomes in terms of 
post-operative pain, post-operative nausea and vomiting (PONV), and length of stay in the post-
anesthesia care unit (PACU)?” 
Bariatric surgery is the last resort for morbidly obese patients who have tried other options, 
such as diet and exercise, but have fallen short of obtaining their desired health goals. The 
surgery is safe and effective, but as with any surgery, there are risks involved. Furthermore, the 
National Institutes of Health (NIH) has put forth very specific criteria that must be met before 
bariatric surgery is approved. The Obesity Action Coalition (2016) lists the following NIH 
criteria: 
1. Body Mass Index (BMI) greater than 40, severe obesity (or weight greater than 100 
pounds over ideal body weight (IBW)) 
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2. BMI 35-40 with significant obesity-related conditions (type two diabetes, high blood 
pressure, sleep apnea or high cholesterol) 
3. No endocrine causes of obesity 
4. Acceptable operative risk 
5. Understands surgery and risks 
6. Absence of drug or alcohol problem 
7. No uncontrolled psychological conditions 
8. Failed attempts at medical weight-loss (diet, other weight-loss options).  
Once the patient has met the required criteria, there are several types of bariatric surgery, which 
include adjustable gastric band, vertical sleeve gastrectomy, Roux-en-Y, and biliopancreatic 
diversion with a duodenal switch.  
Adjustable gastric banding is an example of a non-metabolic bariatric surgery because the 
physiology of storing fat is not altered. It involves the placement of a “belt” around the upper 
part of the stomach, creating a smaller upper pouch that is separated from the rest of the stomach 
(Ogunnaike & Whitten, 2013). This type of surgery also involves a balloon, which can be filled 
with fluid to decrease the space within the stomach and create the illusion of feeling full. 
Although it results in slower weight loss, it avoids the need to cut into the stomach or the 
intestines. Thus, it is minimal surgery that can most often be accomplished laparoscopically and 
avoids any complications with vitamin, mineral, and nutritional absorption problems (Obesity 
Action Coalition, 2016). 
The vertical sleeve gastrectomy is a form of metabolic bariatric surgery because the 
gastrointestinal tract is altered. Most of these surgeries are performed laparoscopically and 
involve the removal of about 75% of the stomach, leaving a gastric “sleeve” and the intestines 
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intact (Obesity Action Coalition, 2016). This is classified as metabolic due to a decrease in 
ghrelin, which is known as the hunger hormone. It is a faster form of weight loss as the patient is 
able to achieve satiety with a smaller amount of intake, but it’s also advantageous in that it does 
not bypass the intestine. As a result, these patients will not experience malabsorption (Obesity 
Action Coalition, 2016).  
The Roux-en-Y procedure differs in that it works by creating a smaller pouch, which reduces 
the amount of intake but also allows the patient to achieve satiety sooner because a part of the 
small intestine is bypassed (Ogunnaike & Whitten, 2013).  This type of surgery causes 
malabsorption and dumping syndrome (Obesity Action Coalition, 2016).  
Lastly, biliopancreatic diversion with duodenal switch is usually performed open and 
involves the removal of two thirds of the stomach, but avoids dumping syndrome by bypassing 
the pancreatic and the bile drainage (Obesity Action Coalition, 2016). This form of bariatric 
surgery offers rapid weight loss by increasing the secretion of Glucagon-like peptide-1 (GLP-1), 
which increases satiety, and by decreasing absorption of fat. As with all bariatric surgeries, a 
commitment to lifestyle changes needs to be made if the patient is not to regain the lost weight.  
The newest form of bariatric surgery is an example of a non-metabolic procedure that 
involves the implantation of electrodes. This is known as vBLOC neuromodulation therapy. The 
placement of the electrodes onto the lower stomach aims to block the vagus nerve, resulting in a 
signaling of feeling full (Obesity Action Coalition, 2016). Weight loss appears to be more 
gradual and complications seem to be rare. Less than four percent of patients have reported any 
complications with the device (Obesity Action Coalition, 2016).  
The choices in bariatric surgeries are many, but the patient population presents with similar 
co-morbidities that can pose a challenge for the anesthesia provider. To understand the obese 
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patient and provide the best and safest anesthesia possible the anesthesia team needs to 
understand the physiological changes in this population, primarily those involving the 
cardiovascular system and the respiratory system. However, it is important to cognize that 
obesity affects every system in the body: gastrointestinal, genitourinary, neurologic, endocrine, 
hematology, musculoskeletal, as well as psychological effects.  
Ogunnaike and Whitten (2013) explain that in an obese patient the total blood volume is 
increased and so is cardiac output. As a result, left ventricular hypertrophy, reduced compliance, 
and impaired filling is seen. The anesthesia provider needs to be cautious in preventing 
intraoperative ventricular failure, which can happen due to fluid overload and as a result of 
negative inotropy of anesthetic agents. Hypoxia or hypercapnia can also lead to pulmonary 
hypertension, further compromising the cardiovascular system. Other cardiac complications seen 
in this patient population include atherosclerosis, coronary artery disease, peripheral vascular 
disease, systemic hypertension, dysrhythmias, and sudden cardiac death (Ogunnaike &Whitten, 
2013).  
Respiratory changes include obstructive sleep apnea, obesity-hypoventilation syndrome, 
asthma, and pulmonary hypertension. Lung compliance is decreased, which leads to a decreased 
functional residual capacity (FRC), vital capacity, and total lung capacity. The decreased FRC is 
a result of a decrease in expiratory reserve volume (ERV). If the ERV is reduced, tidal volumes 
in the lungs are below the closing capacity, which is defined as the volume at which small 
airways begin to close. Ogunnaike and Whitten (2013) further explain that a decrease in ERV 
leads to small airway closure, ventilation-perfusion mismatch, right-to-left shunting, and arterial 
hypoxemia. Combine these physiological changes with anesthesia, which naturally results in a 
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respiratory depression of about 20% in the non-obese patient and 50% in the obese patient, and it 
becomes clear why it is necessary to try to prevent any further respiratory complications. 
Thompson, Bordi, and Boytim (2011), as with many other researchers, agree that obesity 
alters the respiratory function and offer insight in non-pharmacological steps that can be helpful 
in managing this patient population. Due to a reduced FRC and decrease in oxygen reserves, 
oxygen desaturation during induction can be rapid and atelectasis is a continuous threat. Steps 
that have shown to help include pre-oxygenation using positive airway pressure and positive 
end-expiratory pressure (PEEP) along with mechanical ventilation via mask after induction 
(Thompson et al., 2011). Intra-operatively, the anesthesia provider is working against the effects 
of the pneumoperitoneum. Interventions, such as PEEP, high tidal volumes, alveolar recruitment, 
and higher oxygen concentration, have been studied, but no study has shown to be superior. 
Thompson et al. (2011) recommend the following during the maintenance phase of anesthesia: 
maintain a FiO2 less than 0.8, provide recruitment breaths using sustained pressure for 8-10 
seconds greater or equal to 40 cmH2O, use PEEP at 10-12 cmH2O and avoid lung over distension 
by setting tidal volume at 6-10ml/kg using the patient’s ideal body weight (IBW) and 
maintaining the peak-inspiratory pressure less than 30 cmH2O. Post-operatively Thompson et al. 
(2011) recommend that immediately after extubation a continuous positive airway pressure 
(CPAP) or a bi-level positive airway pressure (BiPAP) should be used, along with elevating the 
head of the bed, maintaining good pain control, using incentive spirometry, and encouraging 
early ambulation. The use of opioids makes it more difficult to achieve recovery of respiratory 
function in this patient population.  
 Opioids are known to suppress the respiratory system in all patients, but obese patients are 
more sensitive to the respiratory depressant effect of opioids. Patients may do well intra-
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operatively while intubated. However, when the time comes to extubate, research shows that 
opioid use in the obese patient places the patient at a higher risk of requiring post-operative 
ventilation in order to avoid hypoxic episodes. Patients receiving opioids are also more sedated 
in the PACU, making initiatives such as using an incentive spirometer and early ambulation an 
impossible task. Opioid-free general anesthesia is an alternative option to opioid use, and studies 
have shown that both techniques achieve the same level of pain control but without the side 
effects of the latter option.  
Opioid-free general anesthesia, as the name indicates, is the avoidance of opioids in pain 
treatment pre-operatively, intra-operatively, and post-operatively in an attempt to reduce opioid-
induced respiratory complications without sacrificing patient comfort. Mulier (2012) identifies 
some of the reasons to avoid opioids, besides respiratory depression to be: muscle weakness, 
excessive somnolence, post-operative nausea and vomiting, ileus and constipation, urinary 
retention, dizziness, obstructive breathing, negative inotropism, and the possibility of tolerance 
and addiction. Post-operatively, the patient’s respiratory system may be too depressed to pass 
extubation criteria. If able to extubate, early mobilization may be difficult if the patient is too 
somnolent and experiencing dizziness or PONV, which leads to further complications. Another 
important benefit to opioid-free general anesthesia includes the prevention of opioid-induced 
hyperalgesia, which results in increased pain, thus requiring a higher dose of opioid use to 
adequately control pain. Wound healing can also be impaired, which in a population where 
diabetes is a co-morbidity, can be devastating (Mulier, 2012). Martin, Koodie, and Krishnan 
(2010) dedicated their study to describe how chronic morphine use inhibits wound healing by 
inhibiting immune cell recruitment to the wound. These are all valid reasons why opioids should 
be avoided in bariatric surgery. Leading this cause is Belgian anesthesiologist, Jan Paul Mulier. 
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Mulier’s opioid-free technique has been referred to as the MuliMix, where one to three of the 
following techniques are used, as described by anesthesiologist Adrian Sultana (2016), a 
practicing anesthesiologist in Australia:  
1. Sympatholysis, analgesia, and anesthesia (MAC reduction) with dexmedetomidine  
2. Analgesia with low-dose ketamine 
3. Co-anesthesia and sympatholysis with intravenous lignocaine 
4. Profound neuromuscular blockade maintained up to the end of surgery and appropriately 
reversed 
5. 0.7 -1.0 MAC desflurane in oxygen/air titrated to entropy or BIS EEG monitoring 
6. Magnesium infusion as a further co-analgesic 
Mulier’s technique offers a guideline to alternatives to opioid anesthesia, and many anesthesia 
providers are sharing their modified Mulier’s technique, including Sultana (2016). His modified 
Mulier’s technique is as follows: 
1. Pre-operatively patients are administered 2-3mg of IV Midazolam and an infusion of 
5ug/kg/hr of dexmedetomidine is started. 
2. Intubation is performed with 2mg/kg of IBW of Propofol and 1mg/kg IBW of 
Rocuronium.  
3. Maintenance is then started with 0.5-1.0 MAC of Desflurane and 0.5mg/kg/hr of 
Rocuronium, which is continued for the duration of the pneumoperitoneum.  
4. After the peritoneum is insufflated and trocar placement is achieved, dexmedetomidine 
infusion is decreased to 1ug/kg/hr and further titrated down to 0.5ug/kg/hr, until briefly 
stopped at the completion of surgery. 
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5. IV paracetamol and 40mg of parecoxib are also administered, as well as, local anesthetic 
at the surgical site. 
6. Ondansetron and dexamethasone are administered for their antiemetic and adjunctive 
analgesic effects. 
The research behind this technique includes several small studies, all of which have shown that 
patients receiving non-opioid analgesia, such as that of the MuliMix, fare better than those 
treated with opioid anesthesia.  
The research into non-opioid anesthesia has brought dexmedetomidine, ketamine, lidocaine, 
magnesium, clonidine, and ketorolac into the forefront as alternative non-opioid anesthesia 
adjuncts. The mechanism of action of these adjuncts differs from one another, thus providing 
pain management by targeting multiple sites in the pain pathway. The ideal combination of these 
adjuncts may not be perfected at this time, but understanding the mechanism of action helps the 
anesthesia provider utilize such drugs to their full potential.  
Dexmedetomidine is a central alpha-2 adrenergic agonist, which binds to the G-protein and 
inhibits the L-type calcium channels. Based on the location of the receptor, it can either result in 
sedation if in the locus ceruleus, or provide analgesia if in the spinal cord. The cardiovascular 
system is affected in one of two ways: decrease of tachycardia by inhibiting the cardioaccelerator 
nerve or causing bradycardia via a vagomimetic action (Kaur & Singh, 2011). Gaszynski, 
Czarnik, Laszinski, and Gaszynski (2016) randomly assigned forty-two patients undergoing 
bariatric surgery into either a low-opioid group using dexmedetomidine or a fentanyl-based 
anesthetic group. The researchers concluded that dexmedetomidine provided greater 
hemodynamic stability when compared to those patients intubated using fentanyl, while 
providing equal analgesia. The added benefit to using dexmedetomidine is no respiratory 
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depression, which is a major concern in the obese population. Post-operatively, patients who are 
continued on dexmedetomidine, even as ICU patients, appear to be sedated, but are easily 
aroused. These patients see as much as a 50% reduction in opioid use (Hofer et al., 2005).  
Ketamine is also a non-respiratory depressant adjunct. It is an N-methyl-D-aspartate 
(NMDA) antagonist, which is the receptor responsible for the excitatory neurotransmitter 
glutamate. Some reports indicate that fentanyl can activate NMDA, causing an increase in pain 
sensitivity, but a low dose of ketamine can block this effect. It is important to cognize that high 
doses of ketamine can cause cardiovascular side effects and nightmares; thus, clonidine, an 
alpha-2 agonist, is recommended in conjunction with ketamine. Magnesium works on the same 
NMDA receptor, but in a different mechanism than ketamine; thus, the combination of the two is 
better than one over the other (Feld et al., 2003). Chan and Shetty (2016) looked at the 
relationship of ketamine and magnesium by comparing forty-four obese patients undergoing 
bariatric surgery. All patients received: intravenous acetaminophen, a short acting opiate (either 
remifentanil or fentanyl), a long acting opiate (either morphine or buprenorphine). The port sites 
were also infiltrated with a local anesthetic. The difference was that nine of the forty-four 
patients received only ketamine, five patients received only magnesium, whereas thirty patients 
received both ketamine and magnesium. The study concluded that rescue analgesia in the PACU 
was administered to 56.8% of the patients that received both ketamine and magnesium, whereas 
either ketamine or magnesium treated patients required rescue analgesia at a 71.4% rate. The 
study does have a small population sample, but the results indicate that although both ketamine 
and magnesium are helpful in pain management, the two adjuncts together appear to provide 
better pain control.  
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Lidocaine can be another important adjunct in opioid-free general anesthesia due to its ability 
to inhibit cytokine activity and inflammation in the intestines. The use of lidocaine results in 
decreased bowel recovery time, decreased post-operative pain and a decrease in hospital stay 
(Feld et al., 2003). There have been numerous studies on lidocaine used for pain management. 
De Oliveira, Duncan, and Fitzgerald (2014) performed a randomized, double-blinded placebo-
controlled clinical trial to specifically assess pain control in patients undergoing bariatric 
surgery. Fifty patients were randomly divided into two groups. Group one received a lidocaine 
bolus administration of 1.5mg/kg, which was then followed by a 2mg/kg/h infusion intra-
operatively. Group two was the control group, which received normal saline. The lidocaine 
group experienced a lower consumption of intravenous morphine than the control group, thus 
indicating that systemic lidocaine is an effective adjunct in pain management.  
 Ketorolac, a potent non-steroidal anti-inflammatory drug (NSAID), is yet another adjunct. 
When compared to opioid treated patients, patients on ketorolac experience less PONV, similar 
post-operative pain relief as that of fentanyl, less sedation, earlier bowel function, a decrease in 
hospital stay, and longer acting pain relief than morphine (Feld et al., 2003). Surgeons prefer to 
not use ketorolac in the bariatric population due to increased risk of gastric bleeding, but it is an 
option in the appropriate patient.  
Literature Review 
Feld, Laurito, and Beckerman (2003) randomized thirty obese patients undergoing gastric 
bypass into two groups: one receiving sevoflurane and fentanyl and the other receiving a 
sevoflurane and non-opioid regimen. The non-opioid regimen included ketorolac 30mg at the 
beginning and the end of the case, clonidine 300-500mcg within the first hour of anesthesia start, 
lidocaine 100mg bolus with induction and then 4mg.min-1 for the first hour, 3mg.min-1 for the 
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second hour, 2mg.min-1 until the end of the surgery, ketamine 0.17mg/kg with a maximum dose 
of 1mg/kg, magnesium sulfate 80mg/kg administered with IV fluids, and methylprednisolone 
60mg bolus administered in the holding area. All calculations are based on the patient’s ideal 
body weight (IBW). The data gathered by this study indicated that non-opioid analgesia provided 
adequate intra-operative pain relief and those in the non-opioid group required less morphine in 
the PACU. Also, the pain scores, measured by the visual analogue scale (VAS), were the same 
within the two groups. Another benefit seen was less sedation in the non-opioid group, which 
equated to less time spent in the PACU. Extubation was achieved on all fifteen non-opioid 
anesthesia patients, whereas two of the patients in the fentanyl group remained intubated in the 
PACU. Satisfaction was also measured by VAS and showed that the non-opioid group had 
higher satisfaction levels than the opioid group.  
Monsour, Mahmoud, and Geddawy (2013) present their study, which included 28 patients 
randomly divided between the opioid and non-opioid group. Both groups received the following 
cocktail: ranitidine 50mg (H2 receptor antagonist), metoclopramide 10mg IV and dexamethasone 
8mg IV for PONV prevention, and midazolam 10mg PO for sedation. Induction in the non-
opioid group was performed with propofol 2mg/kg, ketamine 0.5mg/kg, and rocuronium 
0.5mg/kg. The same induction was performed in the opioid group with the exception of 
ketamine, which was replaced with fentanyl 2-5mcg/kg. Both groups were maintained with 
sevoflurane and ketamine or fentanyl infusion respectively. Post-operatively, the non-opioid 
group was treated with paracetamol, diclofenac, and tramadol, whereas the opioid group received 
paracetamol and fentanyl. Both groups had orders for emergent morphine 2-4mg every 2 hours 
as needed. The results of this study showed that not only were there no differences in heart rate, 
mean arterial pressure, O2 sat, and end-tidal CO2, but pain scores and nurse satisfaction were 
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better within the non-opioid group than its counterpart. A side effect experienced by the non-
opioid group that was not seen in the opioid group were hallucinations. This, however, only 
occurred in 7.14% of the patients.   
Lam and Mui (2016) applied a multimodal analgesia model in their bariatric patients, which 
included premedication with pantoprazole 40mg the night before and 2g PO paracetamol and 
150mg or 300mg of PO pregabalin (depending on the BMI) two hours before surgery. Once in 
the operating room, 1-2mg of midazolam was administered; then a dexmedetomidine infusion 
was started at 0.2mcg/kg/hr based on the patient’s lean body weight (LBW). Induction included 
the use of 100mcg of fentanyl, propofol, and either suxamethonium or rocuronium. After 
intubation was achieved, a loading dose of ketamine based on the patient’s LBW was 
administered at a dose of 0.3mg/kg/hr. Parecoxib 40mg, tramadol 100mg, dexamethasone 8mg, 
and tropisetron 5mg were also administered after intubation. A rocuronium drip was titrated to 
maintain one twitch on a train-of-four and desflurane was titrated to maintain a Bispectral Index 
(BIS) value of 40-60. Once closing began, the dexmedetomidine was decreased to 0.1mcg/kg/hr 
then turned off when closure was completed. Once in the PACU, patients were observed for a 
minimal time of 30 minutes and rescue pain and PONV management was available as needed. Of 
the 30 patients that participated in this study, 14 (46.7%) required no further interventions in the 
PACU. Six (20%) patients were given rescue analgesia, but none after PACU discharge, whereas 
10 (33.3%) patients were given rescue analgesia in the PACU and while on the floor. There was 
no control group in this study, thus making it difficult to compare the results; nonetheless this 
study is an important prospective observational case series that is able to demonstrate that about 
half of the patients did not require any further opioid use. It is also important to note that all 30 
patients were able to be extubated prior to their arrival in the PACU. Again, Lam and Mui (2016) 
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do not provide any data that can demonstrate a reduction in respiratory complications, but it is a 
well-known fact that opioids have a respiratory depressant effect and that morbidly obese 
patients are more susceptible. Lam and Mui refer to the Taylor et al. study, which concludes that 
“the use of opioids per se is a risk factor for respiratory events in the first 24 hours after surgery” 
(2016, p. 431). The Ahmad et al. study is also referred by Lam and Mui. In the Ahmad et al. 
study 40 morbidly obese patients underwent laparoscopic bariatric surgery. Their anesthetic 
included desflurane and a remifentanil and morphine administration, which resulted in common 
hypoxic episodes in the first 24 hours. Of the 40 participants, 14 had more than five hypoxic 
episodes per hour (2016).  
Hofer, Sprung, Sarr, and Wedel (2005) presented a case study of a 42-year-old male who is 
morbidly obese (433kg) presenting for bariatric surgery. His comorbidities included obstructive 
sleep apnea, pulmonary hypertension, lower extremity lymphedema, and gastroesophageal 
reflux. Arterial blood gas was obtained and the results were as follows: pH 7.39, PaO2 69 mmHg, 
SaO2 91%, bicarbonate 30mEq, and PaCO2 51 mmHg, and a pulmonary function test that 
indicated a severe restrictive pattern. The patient’s intra-operative pain was strictly treated with 
dexmedetomidine. Post-operatively the patient was transferred to the ICU and remained 
intubated overnight due to not meeting extubation criteria, which he did meet two hours later, but 
the decision was made to leave the patient intubated overnight. Once extubated, the patient’s 
opioid requirements were less, indicating that opioid-free anesthesia is an effective alternative 
pain relief while avoiding opioid-induced respiratory depression. 
A study by Bakhamees, El-Halafawy and El-Kerdawy (2007) showed the same results as that 
of Hofer’s et al. study, but in a larger pool of participants who were scheduled for elective 
laparoscopic Roux-en-Y. Eighty patients were divided into two groups of forty. One group 
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received dexmedetomidine, whereas the second group received a placebo. Intraoperatively the 
dexmedetomidine treated group required less fentanyl and propofol, and post operatively less 
pain was reported when compared to the placebo group. 
Ziemann-Gimmel, Goldfarb, Koppman, and Marema (2014) looked at PONV in bariatric 
surgery using opioid-free total intravenous anesthesia. It is well known that this patient 
population is at an increased risk of PONV, even with the administration of dexamethasone, 
ondansetron and a scopolamine patch. The anesthetic plan in this randomized, parallel group, 
single center study included a premedication with 2-4mg of midazolam. Induction was 
performed using propofol and either succinylcholine or rocuronium in both groups. They also 
received 1,000 mg of acetaminophen intravascularly 20 minutes after induction and 30 mg of 
ketorolac 20 minutes before emergence. The classic group received fentanyl (0.5-1 mcg/kg) 
during induction, and general anesthesia was maintained with either sevoflurane or desflurane. 
Opioids, including fentanyl, morphine, or hydromorphone, were given intra-operative at the 
provider’s judgment. In the TIVA group, a loading dose of dexmedetomidine (0.5 mcg/kg) was 
administered and then a drip was started at 0.1-0.3 mcg/kg, along with an infusion of propofol at 
75-150 mcg/kg. The latter group had a BIS monitor on and drips were titrated to a BIS reading 
between 40 and 60. The study concluded that there was no significant difference in pain, 
indicating that a patient’s pain can be managed without the use of any opioids. The PACU length 
of stay was also insignificant between the two groups, but there was a drastic improvement in 
PONV in the TIVA group when compared to the classic group. Of the 119 participants, 42.7% 
required antiemetic rescue treatment, despite the use of Decadron, Zofran and a scopolamine 
patch. Twenty-two of these patients were in the classic group versus twelve patients in the TIVA 
group. The former also experienced more retching. Overall, Ziemann-Gimmel, Goldfarb, 
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Koppman, and Marema (2014) report a 17.3% decrease in PONV and a decrease in severity of 
PONV. 
Discussion 
All of the studies indicate that post-operative pain management can be reached without any 
or a reduced amount of opioids, but without the opioid side effects. This aids in less PONV 
episodes and less complications from surgery, which can result in a decrease in length of stay in 
the PACU. The latter can be debated, as some studies have shown no statistical significance in 
the length of recovery in the PACU between opioid-free general anesthesia and opioid-based 
general anesthesia. What is well known, however, is that the respiratory function in obese 
patients is already compromised, thus making it imperative to avoid any further decrease in 
respiratory compliance. It is fair to extrapolate that less complications will result in less time 
spent in the PACU. The greatest limitation to these studies is sample size. Most of the studies 
have a small sample population, which can alter the results. Larger studies would be helpful in 
determining a set protocol, and more studies would help to create a greater database. Another 
important limitation is the inconsistency between studies, whether it is medications used, 
measuring tools, or length of observation in the PACU. Perhaps looking at the hospital length of 
stay, rather than only the recovery time in the PACU, might be a better indicator. The PACU 
recovery time can be dependent on different factors, such as bed availability or hospital policies. 
However, even with the various limitations for the obese patients undergoing bariatric surgery, 
the best and safest anesthesia seems to point to an opioid-free anesthesia plan.  
Conclusion 
Anesthesia providers are well versed in the complications that arise from bariatric surgery 
and the co-morbidities that obese patients present with. Understanding the pathophysiology of 
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the obese patients is imperative, but moving forward, improving the safety of anesthesia 
provided to this unique population needs to be further addressed. Using existing research, 
medications such as dexmedetomidine, ketamine, lidocaine, magnesium, and ketorolac have 
shown to be effective pain management alternatives to opioids. Anesthesia providers, such as 
Mulier and Sultana, extrapolated these results into bariatric surgery and reported better post-
operative outcomes. The literature review conducted in this systematic analysis further indicates 
that pain in the obese patient can be managed with an opioid-free anesthetic plan, while avoiding 
opioid-induced complications. Opioid-free anesthesia might be the solution and the future of 
anesthesia management of the obese patient undergoing bariatric surgery, but more evidence-
based research is needed in order to change the practice of anesthesia.  
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